Longitudinal tumor size and NLR as predictive factors of individual survival compared to their baseline values in patients with non-small cell lung cancer treated with durvalumab.

e20047Background: Our ability to accurately predict survival of patients with non-small cell lung cancer (NSCLC) while on treatment is limited. Prognostic markers such as stage and tumor size are w...